Nevro has been granted a patent for implanted pulse generators that reduce power consumption through signal strength-duration characteristics. The technology involves programming the signal generator to increase a signal delivery parameter, such as pulse width or duty cycle, in response to a decrease in available voltage. This allows for more efficient and effective electrical therapy signals to be delivered to patients. GlobalData’s report on Nevro gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Nevro, Neuromodulation implants was a key innovation area identified from patents. Nevro's grant share as of September 2023 was 62%. Grant share is based on the ratio of number of grants to total number of patents.
Implanted pulse generators with reduced power consumption
A recently granted patent (Publication Number: US11766566B2) describes a method and system for programming a signal generator used in stimulation therapy. The method involves increasing a signal delivery parameter of an electrical signal in response to a decrease in available voltage. The increase is based on a correlation between the signal delivery parameter and signal delivery amplitudes, and the signal delivery parameter can be a pulse width and/or a duty cycle.
The patent claims that the signal generator can be programmed to automatically increase the signal delivery parameter when the available voltage decreases. This ensures that the therapy remains effective even when the power supply is low. The correlation between the signal delivery parameter and signal delivery amplitudes can be patient-specific, allowing for personalized therapy.
The signal delivery parameter can be either the pulse width or the duty cycle. The increased pulse width can have a value within a range of 10 microseconds to 333 microseconds, while the increased duty cycle can have a value within a range of 10% to 100%. These ranges provide flexibility in adjusting the signal delivery to suit individual patient needs.
The electrical signal used in the therapy has a frequency range of 1.5 kHz to 100 kHz. Importantly, the signal does not induce paresthesia, which is a tingling or prickling sensation often associated with electrical stimulation. This ensures a comfortable and safe therapy experience for the patient.
The patent also describes a system for providing stimulation therapy. The system includes a signal generator, a processor, and a memory storing instructions. The signal generator is programmed to deliver the electrical signal to the patient. The processor executes the instructions stored in the memory, causing the signal generator to increase the signal delivery parameter based on the correlation between the parameter and signal delivery amplitudes.
In another method described in the patent, the signal generator is programmed to identify an updated therapy amplitude and an updated signal delivery parameter when the available voltage is insufficient to deliver the electrical signal at the target therapy amplitude and target signal delivery parameter. The updated parameters are determined based on a predetermined correlation between amplitude and the signal delivery parameter, which can be patient-specific.
Overall, this patent presents a method and system for programming a signal generator in stimulation therapy that ensures effective and personalized treatment by adjusting the signal delivery parameters based on available voltage and patient-specific correlations.